.
To establish the heterogeneity in which Behçet's disease can manifest, it is important to record the clinical findings of the disease around the world. Here we describe the characteristics of Behçet's disease in the Michigan Behçet's Disease Cohort, based at the University of Michigan. We examine associations between the clinical manifestations of the disease, and compare the ICBD and ISG criteria in our cohort.
Methods
We identified all patients with Behçet's disease who presented to the University of Michigan Health System from October 2011 to June 2017. Only patients who met the International Criteria for Behçet's Disease (ICBD) or the International Study Group (ISG) criteria were included in this study. Basic demographic information including age, sex, race, and ethnicity were recorded. Clinical manifestations and current medications used to treat Behçet's disease in our cohort were also recorded. An experienced rheumatologist (AHS) either directly evaluated each patient or reviewed the medical records of each patient included in this study. Statistical analysis was completed using a chi square test and Yates' correction to determine statistical significance of differences in disease characteristics between men and women, differences between patients who met the ICBD and the ISG criteria, and associations between major and minor disease manifestations.
Results
In total, 114 patients who met the ICBD criteria were included in this study, 76 of whom also met the ISG criteria. As most previous studies on Behçet's disease have used the ISG criteria, we focused our initial analysis on the 76 patients who met the ISG criteria, allowing us to compare results with previous reports (Table 1) . Our ISG criteria cohort consisted of 18 male and 58 female patients. The mean (S.D.) age of this cohort was 40.6 (13.9) years. We had a large majority of White patients, six Black patients, one American Indian and Alaskan Native, two Asian, and four patients whose ancestral background was unknown/other. In addition, the majority of our patients claimed ethnicities of non-Hispanic, 1 was Hispanic, and 5 patients had unknown ethnicities. Patients who met ICBD criteria consisted of 23 men and 91 women ( Table 1 ). The mean (S.D) age of patients in the ICBD cohort was 41.4 (14.5) years. The ICBD cohort also had a large majority of White patients; in addition, there were six Black patients, one American Indian and Alaskan Native, three Asians, and five patients with unknown/other ancestral backgrounds. The ethnicities representing the ICBD cohort were as follows: a large majority of non-Hispanics, 1 Hispanic, and 6 patients with unknown ethnicities.
All patients presented with oral ulcers in the ISG criteria cohort by definition, and all but one had oral ulcers in the ICBD cohort. A majority of the patients in both cohorts had genital ulcers, skin manifestations, and joint involvement (Table 1) The clinical features of the men and women in our cohort were also examined to determine differences between male and female patients ( Table 1 ). The only statistically significant difference noted between male and female patients in our ISG criteria cohort was the prevalence of retinitis, which was 4.6 times more prevalent in men than in women (p=0.0267). Significant differences between disease manifestations in men and women when using the ICBD criteria included arthralgia (p=0.048) and retinitis (p=0.009). Arthralgia was 3.3 times more likely in women than in men, and retinitis was 5.3 times more likely in men than in women.
The current systemic medications used to manage Behçet's disease manifestations in our patients largely consisted of colchicine and prednisone (Table 2 ). These medications were used the most in this cohort, whereas cyclosporine, cyclophosphamide, and apremilast were not used in any of our patients. The biological medications we used to treat our Behçet's disease patients at NYU and 42.9% Behçet's disease patients at the NIH had gastrointestinal manifestations (10) . In contrast, 3.7% of Turkish patients from the University of Istanbul had neurologic disease, while none had gastrointestinal disease (10) . Other Turkish cohort studies have shown similar patterns: gastrointestinal disease has been recorded in 0.4% to 2.7% of Turkish Behçet's disease patients, whereas neuro-Behçet's disease manifests in 1.8% to 3% of patients (12) (13) (14) . Indeed, these previous studies suggest that a smaller proportion of Turkish Behçet's disease patients present with these manifestations than in the United States. We observed a slightly higher frequency of gastrointestinal and neurological involvement in our patients when compared to Turkish cohorts; 5.3% and 6.6% of patients in our ISG cohort had gastrointestinal and neurological involvement, respectively. However, we do not see the drastic differences reported from patients at NYU and the NIH. It is important to note that in our cohort we required consistent MRI findings and colonoscopy features to diagnose neurological and gastrointestinal Behçet's disease, respectively, which could explain this discrepancy.
In our cohort at the University of Michigan, the male to female Behçet's disease ratio occurs similar to cohorts previously studied in the United States. Three other tertiary referral centers in the United States have shown a female predominance of Behçet's disease.
A Behçet's disease cohort at the University of California Davis had a male to female ratio of 1:3.3 using the ICBD criteria, the NIH reported a male to female ratio of 1:4 using the ISG criteria, and NYU noted the largest female dominated cohort with a ratio of 1:11.8, once again using the ISG criteria (10, 15) . In our cohort, we report male to female ratios of 1:3.2 (ISG) and 1:4 (ICBD), supporting a female predominance of Behçet's disease in the United States. It is possible that there are significantly more women than men that present with Behçet's disease in the United States. However, it is also possible that this female bias could be a consequence of studying tertiary referral centers. In fact, the Ambulatory and Hospital Care Statistics Branch of the Center of Disease Control and Prevention surveyed 847 hospital outpatient departments in the United States and found that, in 2011, 76,286 women and 49,435 men visited these participating outpatient clinics (16) . These data suggest that women visit tertiary referral centers more frequently than men in the United States, which might contribute to the female sex bias reported in Behçet's diseases. In France, a study performed in Paris in 2008 seemed to avoid this potential sex bias by including patients from hospitals, community physicians, and the National Health Insurance database. They observed a male to female ratio of 1.3:1 (11) . Nonetheless, more analysis is required as differences in the frequency of tertiary referral center visits in the United States does not account for the entirety of female bias.
The presentation of Behçet's disease manifestations can vary between geographic locations, but it can also vary with sex. In our cohort, we noticed that male and female patients present with Behçet's disease differently (Table 1) . Many previous studies have shown that men have a higher incidence of ocular involvement than women (17) (18) (19) (20) (21) . A Turkish study at the University of Mersin followed 2,313 patients and found that 38.1% of men had ocular involvement, compared to 18.9% of women (17) . While our own ISG criteria cohort data shows no significant difference in overall ocular manifestations between men and women (Men=55.6%, Women=46.6%, p=0.6908), retinitis was significantly more frequent in men (p=0.0267). Similarly, our patients fulfilling the ICBD criteria also showed a higher frequency of retinitis in men compared to women (p=0.009). Most studies reported uveitis and retinitis together as "eye involvement. " However, a study from the United Kingdom with 73 patients reported them separately, noting that 36% of men and only 11% of women had vascular retinitis, thus supporting our own findings (19) .
Two different sets of Behçet's disease criteria were evaluated in this study. Previous research suggests that the ICBD criteria are more sensitive than the ISG criteria, but slightly less specific (2) . The sensitivity of the ICBD criteria is also apparent in our study. Using the ICBD criteria, we identified 38 additional patients compared to using the ISG criteria. Patients fulfilling the ICBD criteria compared to patients fulfilling the ISG criteria were statistically different in the frequency of only skin involvement (p=0.0006) (Figure 1 ). The ISG criteria cohort did not have higher proportions in any of the other manifestations, suggesting that the ISG criteria do not necessarily select patients with more severe disease compared to the ICBD criteria. However, the 38 patients who met the ICBD criteria but not the ISG criteria had experienced significantly fewer disease manifestations ( Table 3 ). The ICBD criteria were able to more frequently identify patients with less severe disease than the ISG criteria.
In conclusion, we describe the clinical characteristics of a relatively large Behçet's disease cohort in Michigan and compare the ISG and ICBD criteria for the first time using a cohort from the United States. This study complements previous literature to understand the heterogeneity of Behçet's disease in different parts of the world and offers insight into the usefulness of the ICBD criteria for identifying Behçet's disease patients in North America. Limitations of our study include the retrospective nature of collecting data from our Financial Disclosure: The authors declared that this study has received no financial support.
